|
FDA Panel to Vote on InterMune Drug for IPF
An FDA advisory panel will consider whether to recommend approval of InterMune’s Esbriet to slow the decline in lung function in patients with
idiopathic pulmonary fibrosis (IPF), after hearing agency staff concerns about proof of efficacy.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives